ANI Pharmaceuticals (NASDAQ:ANIP) Receives “Buy” Rating from HC Wainwright

ANI Pharmaceuticals (NASDAQ:ANIP)‘s stock had its “buy” rating restated by HC Wainwright in a research report issued to clients and investors on Tuesday, Benzinga reports. They presently have a $94.00 price objective on the specialty pharmaceutical company’s stock. HC Wainwright’s target price points to a potential upside of 67.26% from the stock’s previous close.

ANIP has been the topic of several other research reports. Truist Financial reiterated a “hold” rating and set a $60.00 price objective (down previously from $80.00) on shares of ANI Pharmaceuticals in a research report on Wednesday, September 11th. StockNews.com lowered shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, September 7th. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $77.75.

ANI Pharmaceuticals Stock Performance

Shares of ANIP stock opened at $56.20 on Tuesday. ANI Pharmaceuticals has a 52 week low of $48.20 and a 52 week high of $70.81. The company has a market capitalization of $1.18 billion, a price-to-earnings ratio of 35.13 and a beta of 0.71. The company has a 50-day simple moving average of $61.39 and a 200 day simple moving average of $63.93. The company has a debt-to-equity ratio of 0.62, a quick ratio of 3.07 and a current ratio of 3.97.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its quarterly earnings data on Tuesday, August 6th. The specialty pharmaceutical company reported $1.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.95 by $0.07. The company had revenue of $138.00 million during the quarter, compared to analysts’ expectations of $129.09 million. ANI Pharmaceuticals had a return on equity of 15.64% and a net margin of 5.01%. The business’s revenue was up 18.5% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.06 earnings per share. On average, sell-side analysts predict that ANI Pharmaceuticals will post 3.5 earnings per share for the current year.

Insider Activity

In related news, COO Muthusamy Shanmugam sold 14,257 shares of ANI Pharmaceuticals stock in a transaction that occurred on Wednesday, July 17th. The shares were sold at an average price of $63.16, for a total value of $900,472.12. Following the transaction, the chief operating officer now directly owns 635,363 shares of the company’s stock, valued at $40,129,527.08. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, SVP Chad Gassert sold 20,000 shares of the company’s stock in a transaction that occurred on Monday, July 1st. The shares were sold at an average price of $63.44, for a total transaction of $1,268,800.00. Following the completion of the transaction, the senior vice president now directly owns 193,226 shares in the company, valued at approximately $12,258,257.44. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, COO Muthusamy Shanmugam sold 14,257 shares of the firm’s stock in a transaction that occurred on Wednesday, July 17th. The shares were sold at an average price of $63.16, for a total transaction of $900,472.12. Following the completion of the sale, the chief operating officer now owns 635,363 shares in the company, valued at approximately $40,129,527.08. The disclosure for this sale can be found here. In the last three months, insiders sold 66,007 shares of company stock worth $4,089,790. 12.70% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of ANIP. Dimensional Fund Advisors LP increased its holdings in ANI Pharmaceuticals by 6.0% in the 4th quarter. Dimensional Fund Advisors LP now owns 591,731 shares of the specialty pharmaceutical company’s stock worth $32,628,000 after purchasing an additional 33,359 shares in the last quarter. Great Lakes Advisors LLC increased its stake in shares of ANI Pharmaceuticals by 67.1% in the fourth quarter. Great Lakes Advisors LLC now owns 48,252 shares of the specialty pharmaceutical company’s stock valued at $2,661,000 after buying an additional 19,378 shares during the period. Quest Partners LLC bought a new position in ANI Pharmaceuticals in the 4th quarter valued at approximately $150,000. Rubric Capital Management LP boosted its position in ANI Pharmaceuticals by 32.8% during the 4th quarter. Rubric Capital Management LP now owns 1,125,000 shares of the specialty pharmaceutical company’s stock worth $62,032,000 after buying an additional 277,989 shares during the period. Finally, CastleKnight Management LP bought a new stake in ANI Pharmaceuticals during the 4th quarter worth approximately $513,000. 76.05% of the stock is currently owned by institutional investors.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.